Monitoring Requirements for Patients on Eliquis (Apixaban)

Routine Monitoring Requirements

The European Society of Cardiology recommends that patients on Eliquis (apixaban) do not require routine laboratory monitoring of anticoagulation effect, which is one of its primary advantages over warfarin therapy 1, 2
Renal function monitoring is essential as apixaban is partially cleared by the kidneys, with assessment of renal function before starting therapy and at least annually in patients with normal renal function 3, 4
More frequent monitoring (every 3-6 months) is recommended for high-risk patients, including elderly patients, patients with baseline impaired renal function, and patients with conditions that may affect renal function 1, 2, 3

The American Heart Association recommends a dose reduction to 2.5 mg twice daily if a patient has at least two of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1, 5, 4
Apixaban can be used at standard doses for CrCl >30 mL/min, but for severe renal impairment (CrCl 15-29 mL/min), dose reduction may be needed 3, 4

For low bleeding risk procedures, the last dose of apixaban should be taken the morning of the day before the procedure (24-hour window), and resumed at least six hours after the end of the procedure 6, 7
For high bleeding risk procedures, apixaban should be interrupted three days before the procedure, and for very high bleeding risk procedures, longer interruption up to five days may be needed 6, 7
No bridging with heparin is typically required during temporary interruptions 6, 7

Drug interactions should be assessed, including monitoring for interactions with P-glycoprotein inhibitors/inducers and strong CYP3A4 inhibitors/inducers 1, 4
Bleeding risk assessment should include regular clinical evaluation for signs of bleeding, and no specific laboratory test is recommended for routine monitoring of anticoagulant effect 3

Clinical follow-up schedule should be established with regular review of medication adherence, concomitant medications, and signs of bleeding or thrombosis 8, 2
Patient education is essential regarding the importance of adherence to prescribed regimen, recognition and reporting of bleeding symptoms, and informing healthcare providers about apixaban use before procedures 8, 7, 6

Assuming no monitoring is needed at all, while coagulation monitoring isn't required, clinical monitoring and renal function assessment remain important 3, 2
Failure to reassess renal function when patients develop acute illness or start new medications that may affect kidney function 2
Inadequate perioperative management, not stopping apixaban appropriately before invasive procedures, increases bleeding risk 7, 6